Efficacy of current approaches to non-invasive diagnosis of skin cancer and the potential impact of artificial intelligence: A systematic review and meta-analysis.

J Plast Reconstr Aesthet SurgJun 26, 2026 (epub)
Clinical ResearchDermatology

Laura Awad, Samrhuddi Tagalpallewar, Sunil Parthiban et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy of non-invasive skin cancer diagnostic methods, focusing on artificial intelligence (AI) tools. The study analyzed 208 articles and found that AI demonstrated high sensitivity for melanoma diagnosis compared to clinician assessments. AI's performance in diagnosing basal cell carcinoma and squamous cell carcinoma remains uncertain.

Key findings

  • AI interpretation of dermatoscopic images showed high sensitivity for melanoma diagnosis compared to clinician assessments.
  • The diagnostic performance of AI was superior to dermatoscopic assessment alone.
  • Reflectance confocal microscopy has high sensitivity for diagnosing cutaneous malignancy.

Why it matters

The findings highlight the potential of AI to enhance diagnostic accuracy in skin cancer, which could alleviate the burden on healthcare resources and improve patient outcomes, especially in primary care settings.

Source

PubMed · PMID 42585787

Published in J Plast Reconstr Aesthet Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Dermatology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.